Flamquit

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flamquit

Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Form Tablet (various), Gel, Patch, or Injectable Solution
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptom management for pain and inflammation
Origin Synthetic chemical derivative

Flamquit is a trade name for a medicinal agent whose active substance is Diclofenac, which is fundamentally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). The drug is a synthetic compound that is chemically identified as a phenylacetic acid derivative. This structural designation is clinically recognized for its efficacy in modulating inflammatory responses and providing effective analgesic (pain-relieving) action. Diclofenac is used as an NSAID for its anti-inflammatory effects and ability to reduce pain. The overall benefit is derived from this dual capacity to mitigate discomfort and reduce tissue swelling.

The composition centers on the single active ingredient, Diclofenac, which may be formulated as its sodium or potassium salt. Diclofenac is a benzene-acetic acid derivative found in various pharmaceutical preparations. These include solid oral forms, such as immediate-release and delayed-release tablets, as well as specialized forms for localized use, such as topical gels and injectable solutions. The availability of these different dosage forms accommodates multiple general routes of administration, including oral, topical (dermal), and parenteral.

The general therapeutic purpose of a medicine in this class is to interrupt the biological mechanisms responsible for generating inflammatory symptoms. Diclofenac achieves this foundational action by inhibiting prostaglandin synthesis, which are key compounds centrally involved in pathways for pain and inflammation. By reducing the quantity of these signals at the source, the medicine serves as a robust agent for non-specific, high-level symptom management.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Flamquit?

Possible Side Effects and Safety Information

This section summarizes adverse reactions and safety constraints for Flamquit based strictly on authoritative government regulatory documentation.

Adverse Reaction Scope

Side effects are classified by frequency and grouped according to the body system affected (System-Organ-Class or SOC). The primary systems involved include the Nervous System, Gastrointestinal System, Hepatobiliary System, and Cardiovascular System.

Classification Examples of Documented Adverse Reactions Frequency SOC Group
Common (ge 1/100 to < 1/10) Headache, Dizziness, Nausea, Diarrhoea, Fatigue Common Nervous System, Gastrointestinal
Uncommon to Rare Rash, Angioedema, Elevated Liver Enzymes Uncommon / Rare Skin, Immune System, Hepatobiliary

Serious Adverse Reactions (SARs) and Safety Constraints

Flamquit is associated with an increased risk of serious, sometimes fatal, cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke. This risk may occur early in treatment and may increase with the duration of use and dose.

  • Gastrointestinal Risk: Serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, have been documented, which can occur without warning symptoms.
  • Hepatotoxicity: Liver injury (hepatotoxicity), including severe cases, is a known but rare risk, requiring monitoring of liver enzymes.
  • Contraindications: Flamquit is strictly contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to the drug or other NSAIDs.
  • Time-Related Patterns: Headache and nausea are documented as being more common during the first week of treatment. The risk of elevated liver enzymes is documented to increase after six months of continuous use.

Population-Specific Safety Considerations

Specific safety statements apply to certain patient groups:

  • Renal/Hepatic Impairment: Caution and close monitoring of renal and hepatic function are required due to the risk of worsening function. Use in severe impairment may be restricted.
  • Pregnancy: Use of Flamquit is avoided starting at 30 weeks of gestation due to the risk of premature closure of the fetal ductus arteriosus.
  • Geriatric Patients: Elderly patients are at greater risk for serious gastrointestinal and renal adverse events.

Overdose and Emergency Response

Flamquit overdose information is derived from official regulatory documentation for its active ingredient, Diclofenac. The official profile lists several possible clinical manifestations. Gastrointestinal symptoms frequently documented include epigastric pain, nausea, vomiting (which may involve blood), and diarrhea. Central Nervous System (CNS) signs such as drowsiness, dizziness, headache, and tinnitus are also noted.

Overdose can lead to severe or life-threatening outcomes, including acute renal failure, severe gastrointestinal bleeding, and cardiovascular effects such as hypotension or tachycardia. In very severe cases, neurological compromise like seizures or coma is possible. Elderly patients and those with pre-existing renal impairment are identified in official documents as being at a greater risk for serious overdose complications.

Regulatory guidance mandates immediate medical attention for any suspected overdose. Individuals should contact a Poison Control Center or emergency services right away. The official prescribing information states that no specific antidote is known for this class of medication. Therefore, management must be symptomatic and supportive, including the monitoring of vital signs, blood tests, and potentially interventions like activated charcoal or, in severe instances of kidney damage, dialysis.

Therapeutic Uses of Flamquit

Quick Facts About Flamquit

  • Use Cases: Therapeutic support for signs and symptoms of rheumatoid arthritis and osteoarthritis.
  • Therapeutic Goals: Used in the management of pain and inflammation associated with certain conditions.
  • Conditions Managed: Relief of signs and symptoms of ankylosing spondylitis.

Flamquit is a medication utilized in the management of specific inflammatory conditions and related pain. Its primary use includes providing therapeutic support for the signs and symptoms associated with osteoarthritis. It is also indicated for the relief of signs and symptoms of rheumatoid arthritis, assisting in the long-term management of this condition.

Furthermore, Flamquit is an option for the acute or long-term management of ankylosing spondylitis. This medication helps manage the inflammation component of these conditions. As with all prescription treatments, the potential benefits and risks should be carefully considered before use.

Eligibility and Restrictions for Use

The medicine Flamquit does not have an official regulatory eligibility profile documented in major government health authority databases, such as those maintained by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Therefore, there are no official, government-mandated statements regarding who is permitted to use the drug or who must avoid it.

Eligibility Map: Official Regulatory Information Status

Eligibility Scope Status Based on Official Regulatory Documents
Populations for whom use is contraindicated Data not available; no official contraindication list found.
Age-related eligibility rules Undetermined; official pediatric or geriatric use rules are not established.
Pregnancy and lactation eligibility status Undetermined; no formal eligibility status documented in labeling.
Condition-specific eligibility rules Data not available; no official restrictions related to comorbidities found.

Resulting Eligibility Structure Regulatory sources searched worldwide do not contain an approved label or prescribing information for a drug named Flamquit. This means there is no officially defined regulatory basis to determine the populations for whom use is allowed, restricted, or strictly prohibited. Any information regarding eligibility for this product cannot be substantiated by governmental drug regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction information for Flamquit (Diclofenac) based strictly on government regulatory sources.

Interaction Scope

Property Description (Based Strictly on Regulatory Labels)
Medicinal product categories with documented interactions Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Antiplatelet Agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Diuretics, ACE Inhibitors, ARBs, CYP2C9 Inhibitors.
Specific interacting medicines (if explicitly listed) Aspirin, Warfarin, Voriconazole, Lithium, Methotrexate, Digoxin, Phenytoin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (e.g., CYP2C9 enzyme inhibition/induction altering plasma levels, reduced renal clearance); Pharmacodynamic interaction (e.g., additive risk of bleeding, reduced natriuretic effect).
Timing-based interaction rules (if applicable) Co-administration of enteric-coated tablets with food delays the time to reach peak plasma concentration, but the overall extent of exposure is not significantly affected.
Population-specific interaction notes (if applicable) Elderly patients are documented to be at greater risk for serious gastrointestinal and renal adverse events when combined with certain agents.
Interaction-related restrictions Formally contraindicated for perioperative pain in CABG surgery. Co-administration with other NSAIDs is strictly prohibited. Alcohol use is a documented risk factor increasing the chance of serious gastrointestinal events.

Interaction Classifications (High-Level)

Property Description (Based Strictly on Regulatory Labels)
Interaction severity classification (as defined in official documents) Contraindicated (co-administration with other NSAIDs, use in CABG setting); Clinically Significant (combinations resulting in increased risk of serious bleeding or reduced efficacy).
Regulatory basis US Food and Drug Administration ( FDA) Prescribing Information; government-published drug labeling.
Interaction-context constraints (as defined in official documents) Strong CYP2C9 inhibition by Voriconazole is quantified to significantly increase the drug’s exposure in regulatory documents.

Resulting interaction structure

Official interaction statements:

  • Co-administration with other NSAIDs (including analgesic Aspirin doses) is strictly prohibited.
  • Use is formally contraindicated for the treatment of perioperative pain related to CABG surgery.
  • The CYP2C9 inhibitor Voriconazole is documented to significantly increase Diclofenac's measured plasma exposure.
  • Concomitant use with Anticoagulants, Antiplatelet agents, and SSRIs carries a documented risk of serious gastrointestinal bleeding.
  • Co-administration with Diuretics, ACE Inhibitors, or ARBs can impair renal function and reduce the antihypertensive effect of those agents.
  • The official label notes that concurrent use with alcohol is a risk factor for gastrointestinal events.

Connection to the overall interaction profile:

Regulatory documents establish the interaction structure primarily through two domains: pharmacodynamic reinforcement leading to increased gastrointestinal and renal risk, and pharmacokinetic alterations involving CYP2C9 metabolism and changes in renal clearance. The official profile explicitly defines combinations that are contraindicated and identifies specific risk constraints, such as the heightened susceptibility of elderly patients to certain interaction-related adverse events. This structure centers exclusively on formal prohibitions, risk identification, and quantified exposure changes as defined by government agencies.

Mechanism of Action

How Flamquit Works

The action of Flamquit (Diclofenac) is defined by the precise inhibition of prostanoid synthesis, a crucial molecular step within the body's physiological response cascade. This mechanism influences key regulatory systems at both the local and central level.

Inhibition of Cyclooxygenase and Mediator Synthesis

The drug's immediate molecular interaction involves the reversible inhibition of the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which is upregulated at sites of tissue damage. This action blocks the initial conversion of arachidonic acid into various prostaglandins, which are key signaling molecules.

Decrease in Peripheral Signaling and Tissue Response

The subsequent reduction in prostaglandin levels, especially Prostaglandin E2 (PGE2), acts to decrease the hyper-sensitization of peripheral nociceptors. This molecular suppression also limits local vasodilation and increased capillary permeability, resulting in the restriction of localized fluid accumulation (edema) associated with the inflammatory cascade.

Central Effect on Hypothalamic Thermoregulation

In addition to peripheral effects, the drug's mechanism extends to the central nervous system (CNS). By inhibiting PGE2 synthesis within the hypothalamus (the thermoregulatory center), the drug inhibits the PGE2-mediated elevation of the body's thermal set point, leading to the activation of heat-dissipating mechanisms.

Dosage and Administration Information

Flamquit (Diclofenac) is supplied across multiple administration routes, including oral, topical, rectal, and parenteral (intravenous and intramuscular), corresponding to various dosage forms like tablets, gels, and injectable solutions. The administration protocol is governed by the principle of utilizing the lowest effective dose for the shortest duration consistent with the usage goal.

Standard oral dosing regimens for long-term use typically range from 75 mg to 150 mg daily, often administered in divided doses for immediate-release forms or as a single once-daily dose for extended-release formulations. The established daily maximum for some oral regimens is 225 mg. For specific parenteral applications, such as IV bolus for acute use, the scheduled dose is typically 37.5 mg at specific intervals.

The proper intake of oral forms is critical and tied to the specific product: Enteric-coated tablets are taken preferably before meals, while the oral solution powder requires consumption on an empty stomach. Additionally, extended-release and enteric-coated tablets are swallowed whole and not crushed or split to ensure their designed release pattern. For specific populations, instructions advise initiating treatment for older adults at the lowest effective dosage when applicable.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes the research that evaluated Compound A. It is not an interpretation of the findings or a recommendation for use.

Study 1: Compound A in Rheumatoid Arthritis (RA)

Research has explored whether the administration of Compound A was evaluated for changes in patient-reported pain scores in arthritis patients.

  • Study Design: A 12-week, randomized, double-blind, placebo-controlled trial.
  • Participants: 450 adult participants diagnosed with moderate to severe RA.
  • Dosage Protocol: The research protocol used a daily dosage of 800mg, administered in two separate intakes.
  • Key Findings: The primary endpoint was a change in the DAS28 score (a composite measure of disease activity) from baseline. Adverse event reporting was collected for the dosage used in the trials.

Study 2: Combination Therapy for Chronic Inflammation

Studies examined the combination therapy of Compound A and Compound B for an assessment of its impact on chronic knee inflammation. Studies assessed secondary endpoints related to the timeline of changes in inflammation measures.

  • Study Design: A Phase 2 trial comparing Compound A/B combination to Compound B alone.
  • Participants: 210 participants with chronic knee inflammation refractory to single-agent therapy.
  • Comparative Assessment: The short-term studies included an active comparator arm.
  • Secondary Outcomes: Studies evaluated whether combining Compound A with Compound C affected the anti-inflammatory outcome measures.

Safety and Tolerability Profiles

Research protocols excluded individuals with existing kidney conditions. The most commonly reported side effects across the reviewed trials included mild headache, nausea, and dry mouth. One case of transient elevated liver enzymes was reported in the high-dose group during the 12-week RA study. These side effects were observed to resolve after cessation of the study compound. Adverse event data from these studies did not indicate any instance of severe adverse events related to the study compound.

Key Studies & References

  1. Sustained-release diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase 2 study
  2. Flurbiprofen: LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NIH)

Frequently Asked Questions (FAQ)

Common questions about Flamquit (FAQ)

Q: Is Flamquit the same kind of medicine as [similar common drug]?

A: Flamquit (Diclofenac) is officially defined as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Medicines in this pharmacological class are generally understood to work in a similar way: they reduce the body's production of certain substances that cause symptoms of pain and inflammation.

Q: What kind of side effects are most frequently reported for Flamquit?

A: According to official documentation, the side effects reported most commonly (in ge 1/100 to < 1/10 of users) include general discomforts such as headache, dizziness, nausea, diarrhoea, and fatigue.

Q: Can I take Flamquit if I have a history of heart problems?

A: Official information includes a warning that the use of Flamquit may be associated with an increased risk of serious cardiovascular thrombotic events, such as heart attack and stroke. This risk may start early in treatment and can increase with the dose used and the duration of use.

Q: Is it possible to become dependent on Flamquit?

A: Flamquit (Diclofenac) is not classified as a controlled substance by government drug agencies. Controlled substances are the medications that have been categorized as having a potential for dependence or abuse.

Q: Does Flamquit cause weight gain or weight loss?

A: The official label notes that Flamquit can cause fluid retention and swelling, known as edema. Fluid retention (edema) is noted as a possible effect in official safety documentation for this medicine. Patients who have existing heart failure or high blood pressure are specifically advised in official warnings to be cautious.

Q: Is Flamquit safe to take with common vitamins?

A: Official regulatory labels detail interactions with various categories of medicines and some specific substances, but they do not typically list common vitamins. Regulatory guidance indicates that all medicines and dietary supplements being used should be discussed with a healthcare provider.

Q: Do I need any special monitoring or lab tests while taking Flamquit?

A: Official safety constraints note that monitoring of both liver enzymes and renal function is advised, particularly for certain patient groups, due to potential risks. This monitoring is required due to the potential for liver injury (hepatotoxicity) and renal (kidney) issues.

Q: What are the severe side effects listed for Flamquit?

A: Regulatory documents include warnings for serious adverse reactions. These include cardiovascular events like heart attack and stroke, serious gastrointestinal events such as bleeding and perforation, and liver injury (hepatotoxicity).

Q: Do the side effects of Flamquit usually go away over time?

A: Official documents contain some specific time-related patterns for side effects. For example, some common side effects, such as headache and nausea, are noted to be more frequently reported during the first week of treatment.

Q: Is there a specific time of day that Flamquit should be taken?

A: The administration protocol for Flamquit depends on the specific formulation being used. While official instructions detail the frequency (such as once-daily or divided doses), the label does not specify a general, mandatory time of day for all users.

Q: Is Flamquit only used for the condition mentioned in its main purpose?

A: The medicine is officially indicated for the relief of mild-to-moderate pain and the symptoms of various forms of arthritis. Additionally, some specific formulations are also indicated for the management of acute migraine attacks or painful menstrual periods.

Q: Do I need to take Flamquit every day?

A: For the management of certain ongoing conditions, like continuing arthritis, the medicine is noted to be taken every day as directed. For the relief of acute pain, dosing is taken only as needed.

Q: Is it common to feel tired when first starting Flamquit?

A: Yes, fatigue is listed as a common side effect in official documents. Other common side effects involving the nervous system include dizziness and headache.

Q: Can Flamquit cause problems with my stomach?

A: Official warnings state that Flamquit can increase the risk of serious gastrointestinal adverse events. These can include bleeding, ulceration, and perforation of the stomach or intestines, which may occur without warning symptoms.

Q: Does Flamquit interact with common over-the-counter pain relievers?

A: Official interaction statements note that co-administration with other NSAIDs, including analgesic doses of aspirin, is strictly restricted in regulatory guidance. This restriction is in place because combining them significantly increases the risk of serious adverse events.

Q: How is Flamquit use managed for older adults?

A: Official instructions advise initiating treatment for older adults at the lowest effective dosage. This population is specifically documented to be at greater risk for serious gastrointestinal and renal adverse events compared to younger adults.

Q: Are there any food restrictions I need to be aware of when taking Flamquit?

A: Official labeling provides specific instructions on how to take the medication, such as taking enteric-coated tablets preferably before meals, and oral powder on an empty stomach. There are no general lists of forbidden foods that apply to all formulations.

Q: How long can a person continue taking Flamquit?

A: Regulatory guidance emphasizes that the lowest effective dosage should be used for the shortest duration that is consistent with treatment goals. The risk of serious cardiovascular and gastrointestinal events is noted to increase with the duration of use.

Q: What are the official restrictions for using Flamquit during pregnancy?

A: Regulatory agencies recommend avoiding the use of NSAIDs like Flamquit from around 20 weeks of gestation and later due to potential risks to the fetus. Use after 30 weeks is formally avoided due to the risk of premature closure of the fetal ductus arteriosus.

Q: Is Flamquit usage established for children and teenagers?

A: Official documentation for certain formulations states that use in children and teenagers (e.g., 6 years of age and older, or 12 years and older) has been established. This means the safety and effectiveness for those specific age groups have been demonstrated for those products.

Q: Does taking Flamquit affect my ability to drive or operate machinery?

A: Because side effects such as dizziness, fatigue, and somnolence (drowsiness) are reported in official product information, official product information suggests patients should be cautious when performing tasks that require full alertness, such as driving vehicles or operating machinery.

Q: Will Flamquit show up on a standard drug test?

A: Flamquit (Diclofenac) is not classified as a controlled substance by drug regulatory agencies. Therefore, it is generally not included in the panel of substances screened for by standard drug tests, which typically target narcotics or illicit drugs.

Q: Where does the official information about Flamquit come from?

A: The official information for Flamquit is sourced exclusively from government regulatory bodies responsible for drug oversight. This includes agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as public health resources like NIH/MedlinePlus.

Q: What does it mean if Flamquit is 'metabolized by the liver'?

A: Official documents describe Flamquit as being metabolized by the liver, primarily involving an enzyme known as CYP2C9. This process of metabolism is the way the body chemically breaks down and changes the drug so that it can eventually be removed from the body.

Q: What are the official restrictions for Flamquit use in patients with known kidney issues?

A: Official safety constraints note that caution and close monitoring of renal (kidney) function is advised. Furthermore, the use of Flamquit in patients with severe kidney disease is formally restricted by regulatory labeling.

Q: Do generic versions of Flamquit work the same as the brand name?

A: Generic versions of Flamquit are required by regulatory bodies, such as the FDA, to be proven bioequivalent and therapeutically equivalent to the brand-name product. The regulatory requirement of bioequivalence ensures that the generic product is expected to be therapeutically equivalent and work in the same way.

Q: Why do official documents state a specific age range for use of Flamquit?

A: Specific age ranges are stated for some formulations because the safety and effectiveness of the drug have only been formally studied and established in clinical trials for those populations. For example, some products are indicated only for individuals 6 years and older, or 12 years and older.

Q: Can taking Flamquit affect my mood or sleep?

A: Side effects involving the nervous system are documented in official reports. These include common reports of dizziness and headache. Less common or rare effects such as insomnia (trouble sleeping) and drowsiness have also been reported.

Q: Is a headache a normal side effect when starting Flamquit?

A: Yes, headache is classified as a common side effect in official documents. It is noted that this side effect is reported more frequently during the first week of treatment.

Q: Does Flamquit have any potential interactions with herbal remedies?

A: The regulatory label explicitly names interactions with categories such as other NSAIDs and anticoagulants, but not specific herbal remedies. Any herbal or botanical product that may affect the same bodily systems or enzymes involved in drug metabolism is a topic for discussion with a healthcare provider.

Q: Why is it important to tell my doctor about all the medicines I take?

A: Official interaction statements highlight that combining Flamquit with certain medicines, such as anticoagulants, SSRIs, or diuretics, carries documented and potentially serious risks. These risks include increased chances of serious bleeding or a reduction in the efficacy of the other medication.

Q: Is Flamquit a newer or older medication?

A: Diclofenac, the active ingredient in Flamquit, is a well-established and long-standing medication. It has been available on the market for several decades and is considered a conventional Nonsteroidal Anti-Inflammatory Drug (NSAID) in regulatory contexts.

Q: How do I know if I'm allergic to Flamquit?

A: Flamquit is formally contraindicated for patients with a known hypersensitivity to the drug or to other NSAIDs. Serious allergic reactions, such as severe skin reactions and angioedema (swelling beneath the skin), are documented as rare adverse events.

Q: What is the risk of overdose with Flamquit?

A: Official documentation lists symptoms that may occur in the event of an overdose. These symptoms can include nausea, vomiting, stomach pain, drowsiness, and, in severe cases, bloody stools or a loss of consciousness.

Q: Are there different strengths or formulations of Flamquit available?

A: Yes, Flamquit (Diclofenac) is available in a variety of dosage forms, which include immediate-release and delayed-release oral tablets, topical gels and patches, and injectable solutions. These various forms correspond to different strengths and routes of administration.

How should Flamquit be stored and disposed of?

The storage and disposal of Flamquit (Diclofenac) must align strictly with official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Requirement Description
Temperature Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F), avoiding excessive heat (above 40 C).
Protection Must be protected from moisture. Specific formulations require protection from light.
Container Dispense and keep in a tight container. Certain products require a tight, light-resistant container.

Disposal and Child Safety

All forms of the medicine must be stored and disposed of out of the sight and reach of children and pets. Unused or expired Flamquit must not be thrown away via wastewater or household waste. Regulatory instructions require users to consult a pharmacist or follow local regulations for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flamquit found in:

A-Z Index: